Condition
Cryoglobulinemic Vasculitis
Total Trials
6
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Completed2
Unknown2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT02593565Recruiting
Vasculitis Pregnancy Registry
NCT05168475Phase 2Terminated
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
NCT05114109Phase 2Unknown
Isatuximab in Type I Cryoglobulinemia
NCT04692363UnknownPrimary
Plasmapheresis Before Rituximab in Cryoglobulinemia
NCT03410290Completed
Journey of Patients With Vasculitis From First Symptom to Diagnosis
NCT02476292Completed
Impact of Vasculitis on Employment and Income
Showing all 6 trials